Epigenomic ctDNA Assay Predicts Recurrence in Resected Melanoma
An epigenomic ctDNA assay reading methylation signatures predicts recurrence in resected melanoma, potentially guiding adjuvant therapy and follow-up decisions.
Topic
Epigenomics
Topic
Topic
Topic
An epigenomic ctDNA assay reading methylation signatures predicts recurrence in resected melanoma, potentially guiding adjuvant therapy and follow-up decisions.